Literature DB >> 24071455

The real decoy: an antidote for factor Xa-directed anticoagulants.

Calvin H Yeh1, James C Fredenburgh, Jeffrey I Weitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24071455     DOI： 10.1161/CIRCRESAHA.113.302297

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  5 in total

1.  Andexanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants.

Authors:  Jayed H Momin; PharmD Candidate; Gregory J Hughes
Journal:  P T       Date:  2019-09

Review 2.  Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

Authors:  Michelangelo Sartori; Benilde Cosmi
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

Review 3.  Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.

Authors:  Scott Kaatz; Charles E Mahan; Asaad Nakhle; Kulothungan Gunasekaran; Mahmoud Ali; Robert Lavender; David G Paje
Journal:  Curr Cardiol Rep       Date:  2017-10-24       Impact factor: 2.931

Review 4.  Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.

Authors:  Stephanie A Kustos; Pius S Fasinu
Journal:  Medicines (Basel)       Date:  2019-10-15

Review 5.  Reversing factor Xa inhibitors - clinical utility of andexanet alfa.

Authors:  Scott Kaatz; Hardik Bhansali; Joseph Gibbs; Robert Lavender; Charles E Mahan; David G Paje
Journal:  J Blood Med       Date:  2017-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.